Click to Enlarge
Facebook
Twitter
The Financial Times focuses on the pause of the Johnson and Johnson vaccine rollout in Europe as US agencies review concerns over rare blood clots – similar to those seen in the AstraZeneca jab. The US review is due to be complete in “a matter of days”, the paper says, and Johnson and Johnson took the decision itself to halt the use of its jab in Europe.

Financial Times Front Page 19th of May 2025

Boutique lenders, buoyed by post-pandemic optimism, are driving a surge in blank-cheque SPAC deals worth $9bn so far this year, with investors anticipating more lenient oversight coupled with renewed enthusiasm for these specialised investment vehicles.

Read More »